ABSTRACT

BACKGROUND: Patient approaching hospital with the chest pain or other acute coronary syndrome signs or symptoms evaluation is time taking, pricey, complex and challenging. Raised biomarkers of necrosis including oxidative stress, cytokines, cell adhesive molecules, biomarker of destabilization of formed plaque and rupture, ischemia biomarkers and myocardial stretch biomarker endow initial outlook of patient’s overall risk and also be familiar with high risk patients of adverse events. METHODOLOGY: Different biomarkers of AGEs, AOPPs, lipid biomarkers, and inflammatory markers among 132 control and acute coronary syndrome patient’s serum samples via different lab tests and ELIZA kits were assessed. The results were analyzed by independent ttest in SPSS version 21. RESULTS: Significantly increasing trends of MDA (0.911±0.033 nmol/ml vs. 4.19±1.09 nmol/ml), NO (20.59±1.89 ng/ml vs. 81.25±5.19ng/ml), AGEs (0.61±0.014 ng/ml vs. 4.19±0.48 ng/ml) and AOPPs (95.65±5.19ng/ml vs. 133.26±10.32ng/ml) was depicted in patients of ACS than controls. Results on the subject of lipid profile biomarkers TCh (4.59±0.59 mmol/L vs. 9.65±2.16 Mmol/L), triglycerides (1.08±0.017 mmol/L vs. 5.19±1.48 mmol/L), and LDL (2.18±0.008 mmol/L vs. 3.29±0.011 mmol/L) showed significantly increasing pattern with reduction in HDL (1.79±0.018 mmol/L vs. 0.985±0.008 mmol/L) levels in ACS patients. The scrutiny of inflammatory biomarkers including IL-1? (8.19±1.99 pg/ml vs. 3.99±0.32 pg/ml) and TNF-? (41.58±6.35 pg/ml vs. 21.25±4.29 pg/ml) portrayed augmented picture in disease patients in contrast to healthy controls’. The study also reveals that MMP-11 (96.35±5.18ng/ml vs. 41.59±5.26ng/ml) level was increased in acute coronary syndrome patients as compared to normal individuals. CONCLUSION: This study corroborates that activation and progression of local and systemic inflammation as the result of elevated inflammatory markers (IL-1?, TNF-a and MMP-11) and oxidative markers especially AGEs, AOPPs, NO and MDA may consider to have a supportive pathogenic role in acute coronary syndrome and could identify high-risk patients with subsequent increase ischemic events and vulnerable plaque destabilization. Keywords: Acute coronary syndrome, advanced glycation end products, advanced oxidation protein products, matrix metalloproteinase
Publication date: 01/04/21

https://ijbpas.com/pdf/2021/April/MS_IJBPAS_2021_5463.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2021/10.4.5463